MA-GILLETTE
Gillette (NYSE: PG), the world’s largest male grooming company and brand pioneer in gaming and esports, proudly announced the return of the highly anticipated Gillette Cup Featuring Fortnite, a two-day international gaming competition featuring a custom-built island in Fortnite. First played in February 2022, the inaugural Gillette Cup garnered over 300,000 viewing hours throughout the tournament. Back for its second year, the event kicks off on June 1, 2023, and will unite members of the Gillette Gaming Alliance as they compete against members of the global Fortnite community for $50,000 -- doubling the prize pool from last year. The Gillette Cup Featuring Fortnite is among one of the largest branded tournaments to date for the gaming community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005178/en/
Gillette celebrates return of Gillette Cup Featuring Fortnite with all-star Gillette Gaming Alliance. (Photo: Business Wire)
The competition will be played on a revamped “Gillette Face-Off” island, a custom environment developed using Fortnite’s Creative toolset; this builds on the success of the island’s existing futuristic lab and mineshaft versions, which were first introduced in 2022. The custom branded Fortnite islands feature action-packed “Zero Build” gameplay and iconic Gillette products for a gaming experience as satisfying as a close shave. To compete in the “Gillette Face-Off” islands at any time, use island code 6674-8139-7577.
“The celebrated return of the Gillette Cup Featuring Fortnite is testament to our previous successes and deepening relationship with Gillette Gaming Alliance members to provide meaningful and impactful experiences to the gaming community,” explains Daniel Ordonez, Gillette Global Brand Franchise Leader. “We are looking forward to cheering on our Alliance members and engaging with Fortnite’s community – while, most importantly, meeting them where they thrive in a truly fun and authentic way.”
For the first time, viewers and fans worldwide can visit www.GilletteCup.com to check out the leaderboard and tune-in for real-time updates. Additionally, they will have the chance to win exclusive Gillette Gaming gear and products by visiting the newly launched website throughout the tournament.
Tournament Details – Competitive, Professional Sporting Event Style Format
The tournament will kick off with the Regionals Round, where eight (8) teams of “Duos,” representing eight (8) countries/regions will compete – totaling 64 teams and 128 players across the globe. Participants will represent Brazil, France, Germany, Italy, Mexico, Spain, United Kingdom, and USA/Canada. Using a points system, teams will be randomly placed on the “Gillette Face-Off” island and compete in multiple rounds of Zero Build matches.
The top 16 teams from Regionals will compete for the opportunity to advance to Semi-Finals and be divided into two (2) groups of eight (8) Duos. These 16 teams will continue to compete in multiple rounds of the “Gillette Face-Off” island. The top four (4) Duos from each group will advance to the Finals to form a single lobby and compete in multiple rounds of the Gillette Cup custom island. The Duos will be scored using the points system and awarded cash prizing, based on how they rank. The last Duo standing will be named winner of the Gillette Cup!
Gillette Gaming Alliance members – inclusive of TypicalGamer (USA/Canada), Vicens (Spain), Agustin (Spain), Papaplatte (Germany), Rumathra (Germany), Elded (Mexico), Jolavanille (France), Pizfn (Italy), Xuider (Italy), Mongraal (United Kingdom), and Nobru (Brazil) – will represent their respective countries as they battle it out against fellow professional members of the Fortnite community to bring home the “win” and championship prize.
“I have had a blast streaming for the Gillette Gaming Alliance this year and providing awesome content and experiences to my community on behalf of the brand,” shares Fortnite pro Andre Rebelo, also known as TypicalGamer, Gillette Gaming Alliance member representing North America. “I remember tuning into the Gillette Cup last year and thinking it was epic. So, I am really excited to be a part of it myself this year – and I hope to bring home the W for my fans and followers.”
The Gillette Gaming Alliance, now in its fifth year, serves as Gillette’s longest running gaming activation as well as one of the most defining and successful programs to date for the brand.
*This is an independently created Fortnite Creative experience and is not sponsored, endorsed, or administered by Epic Games, Inc.
About Gillette
For more than 120 years, Gillette has delivered precision technology and unrivaled product performance – improving the lives of over 800 million consumers around the world. From shaving and body grooming, to skin care and sweat protection, Gillette offers a wide variety of products including razors, shave gel (gels, foams and creams), skin care, after shaves, antiperspirants, deodorants and body wash. For more information and the latest news on Gillette, visit www.gillette.com. To see our full selection of products, visit www.gillette.com. Follow Gillette on Twitter, Facebook and Instagram.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper® The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005178/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom